Are you attending the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting? You can't miss this networking event about nuclear medicine and molecular imaging if you want to to stay up-to-date with recent developments. To learn more about the role of nuclear imaging in clinical trials and other research, you need to meet with TRACER. Our unique approach to imaging in clinical trials offers drug developers many benefits. Learn how you can start your clinical trials in-patient before Phase 1 and with only an extended single-dose toxicity study and even without GMP material. Let's talk at the SNMMI meeting.
Our VP Technology Assessment, Maarten Brom, and VP Commercial Operations, Tessa Aminetzah, will represent TRACER and participate in the meetings.
You can use this opportunity to discuss the use of imaging in your research. Fill out the contact form on this page and we will get back to you soon.
We are excited to meet you!